EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology

APMIS

Volumn 116, Issue 1, 2008, Pages 27-32

  Leibl, Sebastian ^a   Zigeuner, Richard ^a   Hutterer, Georg ^a   Chromecki, Thomas ^a   Rehak, Peter ^a   Langner, Cord ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

EGFR; Metaplasia; Targeted therapy; Upper urinary tract; Urothelial carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; UNIVARIATE ANALYSIS; URINARY TRACT CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METAPLASIA; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 38849110197     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2008.00859.x     Document Type: Article

References (35)

1. Genega EM, Porter CR. Urothelial neoplasms of the kidney and ureter. An epidemiologic, pathologic, and clinical review. Am J Clin Pathol 2002 117 : S36 48.
2. Kirkali Z, Tuzel E. Transitional cell carcinoma of the ureter and the renal pelvis. Crit Rev Oncol Hematol 2003 47 : 155 69.
3. Adam L, Kassouf W, Dinney CP. Clinical applications for targeted therapy in bladder cancer. Urol Clin North Am 2005 32 : 239 46.
4. McHugh LA, Griffiths TR, Kriajevska M, Symonds RP, Mellon JK. Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer. Urology 2004 63 : 619 24.
5. Langner C, Gross C, Rehak P, Ratschek M, Ruschoff J, Zigeuner R. HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique. Urology 2005 65 : 176 80.
6. Nakanishi K, Kawai T, Suzuki M, Torikata C. Growth factors and oncogene products in transitional cell carcinoma. Mod Pathol 1996 9 : 292 7.
7. Tsai YS, Tzai TS, Chow NH, Wu CL. Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract. Urology 2005 66 : 1197 202.
8. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003 8 : 303 6.
9. Sobin LH, Wittekind C. UICC: TNM classification of malignant tumors, 6th ed. New York : Wiley-Liss, 2002.
10. Lopez-Beltran A, Sauter G, Gasser T, Hartmann A, Schmitz-Dräger BJ, Helpap B, et al. Tumours of the urinary system. Infiltrating urothelial carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs. Lyon : IARC Press, 2004 93 109.
11. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998 4 : 844 7.
12. Dei Tos AP, Ellis I. Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur J Cancer 2005 41 : 1383 92.
13. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? J Clin Pathol 2004 57 : 773 5.
14. Langner C, Hutterer G, Chromecki T, Rehak P, Zigeuner R. Patterns of invasion and histological growth as prognostic indicators in urothelial carcinoma of the upper urinary tract. Virchows Arch 2006 448 : 604 11.
15. Sauter G, Haley J, Chew K, Kerschmann R, Moore D, Carroll P, et al. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 1994 57 : 508 14.
16. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001 7 : 1957 62.
17. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994 69 : 1120 5.
18. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990 65 : 1619 25.
19. Nguyen PL, Swanson PE, Jaszcz W, Aeppli DM, Zhang G, Singleton TP, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 1994 101 : 166 76.
20. Popov Z, Gil-Diez-De-Medina S, Ravery V, Hoznek A, Bastuji-Garin S, Lefrere-Belda MA, et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 2004 22 : 93 101.
21. Rajjayabun PH, Keegan PE, Lunec J, Mellon JK. erbB receptor expression patterns in human bladder cancer. Urology 2005 66 : 196 200.
22. Rotterud R, Nesland JM, Berner A, Fossa SD. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 2005 95 : 1344 50.
23. Turkeri LN, Erton ML, Cevik I, Akdas A. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology 1998 51 : 645 9.
24. Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CH, et al. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 1991 63 : 967 70.
25. Imai T, Kimura M, Takeda M, Tomita Y. Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder. Br J Cancer 1995 71 : 69 72.
26. Jenkins BJ, Martin JE, Baithun SI, Zuk RJ, Oliver RT, Blandy JP. Prediction of response to radiotherapy in invasive bladder cancer. Br J Urol 1990 65 : 345 8.
27. Martin JE, Jenkins BJ, Zuk RJ, Blandy JP, Baithun SI. Clinical importance of squamous metaplasia in invasive transitional cell carcinoma of the bladder. J Clin Pathol 1989 42 : 250 3.
28. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ayala AG, Ro JY, et al. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol 1989 141 : 33 7.
29. Raghavan D. Progress in the chemotherapy of metastatic cancer of the urinary tract. Cancer 2003 97 (8 Suppl 2050 5.
30. Russell PJ, Jelbart M, Wills E, Singh S, Wass J, Wotherspoon J, et al. Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation. Int J Cancer 1988 41 : 74 82.
31. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004 10 : 4874 84.
32. Kassouf W, Luongo T, Brown G, Adam L, Dinney CP. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 2006 176 : 787 92.
33. Maddineni SB, Sangar VK, Hendry JH, Margison GP, Clarke NW. Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br J Cancer 2005 92 : 125 30.
34. Nicolle G, Daher A, Maille P, Vermey M, Loric S, Bakkar A, et al. Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. Clin Cancer Res 2006 12 : 2937 43.
35. Nutt JE, Lazarowicz HP, Mellon JK, Lunec J. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 2004 90 : 1679 85.